Hyung-Min Kwon1, Yong-Seok Lee, Hee-Joon Bae, Dong-Wha Kang. 1. From the Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea (H.-M.K., Y.-S.L.); Department of Neurology, Seoul National University Bundang Hospital, Seongnam, South Korea (H.-J.B.); and Department of Neurology, Asan Medical Center, Seoul, South Korea (D.-W.K.).
Abstract
BACKGROUND AND PURPOSE: Hyperhomocysteinemia is a well-known risk factor for vascular disease. However, its action, mechanism, and role in the acute phase of stroke have not been determined. We tried to determine whether an association existed between elevated serum homocysteine levels and early neurological deterioration (END) in patients with acute ischemic stroke. METHODS: We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirinwithin 48 hours of an acute ischemic stroke. END was defined as an increase of ≥1 point in motor power or an increase of ≥2 points in the total National Institute of Health Stroke Scale score within 7 days. RESULTS: The mean (±SD) serum homocysteine level was 11.4±4.7 μmol/L. Of the 396 patients studied, 57 (14.4%) patients worsened during the 7 days after inclusion. Most (68%) of the END cases occurred within the first 24 hours after treatment. High levels (>10.3 μmol/L) of serum homocysteine were independent predictors for END (third quartile odds ratio, 3.45; 95% confidence intervals, 1.25-9.50; P=0.016; fourth quartile odds ratio, 3.36; 95% confidence intervals 1.18-9.52; P=0.023) in multivariate analysis. CONCLUSIONS:Patients with acute stroke with elevated serum homocysteine levels are at an increased risk for END.
RCT Entities:
BACKGROUND AND PURPOSE:Hyperhomocysteinemia is a well-known risk factor for vascular disease. However, its action, mechanism, and role in the acute phase of stroke have not been determined. We tried to determine whether an association existed between elevated serum homocysteine levels and early neurological deterioration (END) in patients with acute ischemic stroke. METHODS: We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke. END was defined as an increase of ≥1 point in motor power or an increase of ≥2 points in the total National Institute of Health Stroke Scale score within 7 days. RESULTS: The mean (±SD) serum homocysteine level was 11.4±4.7 μmol/L. Of the 396 patients studied, 57 (14.4%) patients worsened during the 7 days after inclusion. Most (68%) of the END cases occurred within the first 24 hours after treatment. High levels (>10.3 μmol/L) of serum homocysteine were independent predictors for END (third quartile odds ratio, 3.45; 95% confidence intervals, 1.25-9.50; P=0.016; fourth quartile odds ratio, 3.36; 95% confidence intervals 1.18-9.52; P=0.023) in multivariate analysis. CONCLUSIONS:Patients with acute stroke with elevated serum homocysteine levels are at an increased risk for END.
Authors: Martin Petráš; Anna Drgová; Mária Kovalská; Zuzana Tatarková; Barbara Tóthová; Oľga Križanová; Ján Lehotský Journal: Cell Mol Neurobiol Date: 2017-02-16 Impact factor: 5.046
Authors: Lisa Cloonan; Kaitlin M Fitzpatrick; Allison S Kanakis; Karen L Furie; Jonathan Rosand; Natalia S Rost Journal: Atherosclerosis Date: 2015-03-02 Impact factor: 5.162
Authors: Jan Lehotsky; Martin Petras; Maria Kovalska; Barbara Tothova; Anna Drgova; Peter Kaplan Journal: Cell Mol Neurobiol Date: 2014-09-07 Impact factor: 5.046
Authors: Wenjun Deng; David McMullin; Ignacio Inglessis-Azuaje; Joseph J Locascio; Igor F Palacios; Ferdinando S Buonanno; Eng H Lo; MingMing Ning Journal: Neurology Date: 2021-05-13 Impact factor: 11.800